Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT).
Fukuda I, Hirayama A, Kawasugi K, Kobayashi T, Maeda H, Nakamura M, Nakanishi N, Yamada N, Tajima T, Iwashiro S, Okayama Y, Sunaya T, Hirano K, Hayasaki T. Fukuda I, et al. Among authors: hayasaki t. TH Open. 2021 Oct 7;5(4):e521-e532. doi: 10.1055/a-1664-1164. eCollection 2021 Oct. TH Open. 2021. PMID: 34877450 Free PMC article.
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.
Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Okayama Y, Sunaya T, Hirano K, Hayasaki T. Ikeda T, et al. Among authors: hayasaki t. PLoS One. 2021 Jun 11;16(6):e0251325. doi: 10.1371/journal.pone.0251325. eCollection 2021. PLoS One. 2021. PMID: 34115769 Free PMC article.
Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub-analysis from the XAPASS study.
Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Tachiiri M, Okayama Y, Sunaya T, Hirano K, Hayasaki T. Ikeda T, et al. Among authors: hayasaki t. J Arrhythm. 2022 Mar 20;38(3):369-379. doi: 10.1002/joa3.12700. eCollection 2022 Jun. J Arrhythm. 2022. PMID: 35785372 Free PMC article.
Safety Profile and Effectiveness of Rivaroxaban for Patients With Venous Thromboembolism in Japan　- Results From Post-Marketing Surveillance (XASSENT).
Fukuda I, Hirayama A, Kawasugi K, Kobayashi T, Maeda H, Nakamura M, Yamada N, Tajima T, Tachiiri M, Okayama Y, Sunaya T, Hirano K, Hayasaki T. Fukuda I, et al. Among authors: hayasaki t. Circ J. 2023 Aug 25;87(9):1175-1184. doi: 10.1253/circj.CJ-23-0104. Epub 2023 May 27. Circ J. 2023. PMID: 37245989 Free article.
Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.
Akizawa T, Yamada T, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Yamamoto H. Akizawa T, et al. Among authors: hayasaki t. Kidney Int Rep. 2021 Jul 23;6(10):2604-2616. doi: 10.1016/j.ekir.2021.07.015. eCollection 2021 Oct. Kidney Int Rep. 2021. PMID: 34622100 Free PMC article.
40 results